Anebulo Pharmaceuticals Files 8-K
Ticker: ANEB · Form: 8-K · Filed: Jun 17, 2024 · CIK: 1815974
| Field | Detail |
|---|---|
| Company | Anebulo Pharmaceuticals, Inc. (ANEB) |
| Form Type | 8-K |
| Filed Date | Jun 17, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: administrative, contact-update
TL;DR
Anebulo Pharma updated its address and phone number in a new 8-K filing.
AI Summary
Anebulo Pharmaceuticals, Inc. filed an 8-K on June 17, 2024, reporting an event on June 13, 2024. The filing indicates the company's principal executive offices are located at 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734, and provides their telephone number as (512) 598-0931.
Why It Matters
This 8-K filing provides updated contact and location information for Anebulo Pharmaceuticals, Inc., which is important for investors and stakeholders to have the correct details for communication.
Risk Assessment
Risk Level: low — This filing is administrative and does not contain significant financial or operational news.
Key Players & Entities
- Anebulo Pharmaceuticals, Inc. (company) — Registrant
- 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734 (location) — Principal executive offices
- (512) 598-0931 (phone_number) — Registrant's telephone number
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 13, 2024.
What is the company's primary business classification according to the filing?
The company is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are Anebulo Pharmaceuticals, Inc.'s principal executive offices located?
The principal executive offices are located at 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734.
What is the telephone number provided for Anebulo Pharmaceuticals, Inc.?
The telephone number is (512) 598-0931.
What is the state of incorporation for Anebulo Pharmaceuticals, Inc.?
The state of incorporation is Delaware.
Filing Stats: 555 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2024-06-17 16:05:40
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ANEB The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 39KB
- 0001493152-24-024096.txt ( ) — 210KB
- aneb-20240613.xsd (EX-101.SCH) — 3KB
- aneb-20240613_lab.xml (EX-101.LAB) — 33KB
- aneb-20240613_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANEBULO PHARMACEUTICALS, INC. Date: June 17, 2024 By: /s/ Richard Anthony Cunningham Richard Anthony Cunningham Chief Executive Officer ( Principal Executive Officer )